How to Buy Protagonist Therapeutics Stock
Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. , a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases.
Protagonist Therapeutics stock last closed at $25.15, up 1.99% from the previous day, and has increased 8.13% in one year. It has overperformed other stocks in the Biotechnology industry by 0.3 percentage points. Protagonist Therapeutics stock is currently +83.31% from its 52-week low of $13.72, and -24.57% from its 52-week high of $33.34.
At the moment, there are 58.27M PTGX shares outstanding. The market capitalization of PTGX is $1.47B. In the past 24 hours, 375,548 PTGX shares were traded.
How to Buy Protagonist Therapeutics Stock
Wondering how to invest in Protagonist Therapeutics stock? Here's how.
- Figure out where to buy Protagonist Therapeutics stock: You need to pick an online brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you choose where to buy Protagonist Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Put funds into your investment account: Pick your method of payment and add your information.
- Analyze Protagonist Therapeutics stock: The Protagonist Therapeutics ticker symbol is PTGX. Is Protagonist Therapeutics stock a good investment? Should you buy shares of PTGX? How do PTGX's underlying business fundamentals look? Do top analysts think Protagonist Therapeutics is a good buy? Why has PTGX's stock price moved recently? (Hint: Our stock market analysis website can help you decide if PTGX is a good stock to buy).
- Make your PTGX buy order: Decide if you will purchase PTGX shares at the current market price or use a limit order to purchase PTGX shares at a specific price.
- Keep an eye on your PTGX investment: Create a watchlist to watch your new investment in Protagonist Therapeutics shares.
Step 1: Figure out where to buy Protagonist Therapeutics stock
You will need a brokerage account to access the NASDAQ market and buy PTGX stock.
Our favorite brokerage: eToro
We believe that eToro is the best place to buy stocks. Here's why:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to global markets: From Tech to Healthcare, New York to Hong Kong — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now.
Open eToro AccountStep 2: Open your brokerage account
Now that you've picked the best brokerage, the next step is to fill out some personal information so you are able to invest in PTGX today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to create a new brokerage account.
- Submit your info by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you have created your account on our top ranked stock app, you need to deposit funds:
Watch this video walkthrough if you need help depositing funds into your new investment account.
Step 4: Analyze Protagonist Therapeutics stock
After you have decided on the best place to buy Protagonist Therapeutics stock, it's very important to analyze their stock prior to investing, so you truly comprehend the risk as well as the upside.
Protagonist Therapeutics Metrics
Protagonist Therapeutics Due Diligence Checks
WallStreetZen was created to help part-time investors perform more in-depth fundamental analysis in less time.
You can view all of the due diligence checks on PTGX's stock page.
Is PTGX stock properly valued?
Investors use many financial metrics, analyses, models, and charts to gauge PTGX's fair value.
Using relative valuations metrics:
- PTGX could be undervalued based on its P/B ratio of 4.35x, relative to Biotechnology industry P/B ratio of 5.85x
You can do more valuation analysis on PTGX's stock here.
A quick look at PTGX Financials
Signs that PTGX is financially healthy:
- PTGX has $341.62M in cash and short term investments. This is enough to cover its annual cash burn of $70.85M.
- There are more short-term assets than short-term liabilities on the PTGX balance sheet.
- PTGX has a low debt to equity ratio of 0.06.
- Total PTGX debt is lower than 5 years ago, relative to shareholder equity.
- PTGX has cash burn of 70845000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the PTGX balance sheet.
Signs that PTGX is not financially healthy:
- PTGX profit margin has gone up by 3.48 percentage points in the past year, but the company is still unprofitable.
Is Protagonist Therapeutics stock a Buy, Hold, or Sell, according to analysts?
Out of 3 Wall Street analysts who give recommendations on PTGX, the consensus analyst rating on PTGX is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are forecasting on the Protagonist Therapeutics stock forecast page.
PTGX Technicals
Is PTGX Growing Revenue?
Last year, PTGX revenue was $60.00M. In the past 5 year, PTGX's revenue has grown by 14.17% per year. This was slower than the Biotechnology industry average of 28.56%.
You can analyze PTGX's earnings and revenue performance here.
Who is buying/selling PTGX?
In the past 12 months, insiders at PTGX have sold more shares than they have bought.
Asif Ali, Chief Financial Officer of PTGX, was the latest PTGX insider to sell. They sold $30,985.74 worth of PTGX stock on Apr 18, 2024.
Learn more about who owns PTGX stock here.
Does PTGX provide a stable income stream?
No, Protagonist Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about PTGX?
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Make your PTGX buy order
There are two primary order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are generally fine. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a specific price, use a limit order.
Click the Open Trade button and eToro will execute your order.
If you need additional help buying stocks on eToro, watch the helpful video below:
Step 6: Keep an eye on your PTGX investment
Now that you own some shares in PTGX, you'll want to keep up with your new investment.
Add PTGX to a watchlist to track the most important metrics related to your PTGX stock.
PTGX Feed
How to Buy Stock in Protagonist Therapeutics
To summarize, here are the 6 steps to buy stock in Protagonist Therapeutics:
- Figure out where to buy Protagonist Therapeutics stock
- Open your brokerage account
- Put funds into your investment account
- Analyze Protagonist Therapeutics stock
- Make your PTGX buy order
- Keep an eye on your PTGX investment
If you need a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to watch your investment in Protagonist Therapeutics, get started below.
Other Stock Buying Guides You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.